AWG News

Home / AWG News

Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WASHINGTON, April 20, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be held April 21 – 24 in Madrid, Spain. ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases. “AWG is proud to share that data from our member companies covering a vast swath of infectious disease topics will be presented at ECCMID 2018,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “Representatives from AWG companies will be participating in over 70 different oral sessions and poster presentations showcasing developments in innovative antifungal and antibacterial therapies, in addition to progress related to therapeutic antibodies, new diagnostic tools, and more.” The following AWG member companies will be presenting at ECCMID 2018: Arsanis Inc. (NASDAQ: ASNS) , Amplyx Pharmaceuticals, Cidara Therapeutics, Inc. (NASDAQ: CDTX) , ContraFect...

Read More

The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair

WASHINGTON, Jan. 30, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today that Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics, has been appointed as Vice Chair, joining Vice Chair Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) and Chairman Jeffrey Stein, Ph.D., President and CEO of Cidara Therapeutics, Inc. (NASDAQ: CDTX). “On behalf of AWG, I would like to welcome Dr. Dunne as Vice Chair,” said Dr. Jeffrey Stein, AWG Chairman. “As an infectious disease physician and long-standing member of AWG, the Board of Directors is confident Dr. Dunne will contribute valuable insight in the position as Vice Chair.” “I’m delighted to serve as Vice Chair of our coalition of infectious disease companies committed to advancing innovations in antimicrobial drug and diagnostic device development,” said Dr. Michael Dunne. “I look forward to the opportunity to engage with the leadership of AWG to promote legislation and regulatory policies that address barriers that hinder an emerging company’s ability to develop new treatment options for serious, and life-threatening diseases.” All pharmaceutical and biotechnology companies developing new antimicrobial therapeutics and rapid diagnostic devices are eligible for consideration of membership in AWG. If you are interested in learning more about becoming a member...

Read More

Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group

WASHINGTON, Jan. 29, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (Nasdaq: SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Additionally, AWG recently welcomed Vical Incorporated (Nasdaq: VICL), a biopharmaceutical company focused on the development of products for the prevention and treatment of chronic or life-threatening infectious diseases based on patented DNA delivery technologies and other therapeutic approaches. These new additions bring AWG’s membership to 17 antimicrobial drug and diagnostic device development companies. “Since AWG was founded in 2012, the coalition has grown substantially in size and scope, and has become increasingly influential in driving legislation and public policy that promote innovation in the treatment of infectious diseases,” said Jeffrey Stein, Ph.D., Chairman of AWG. “Through the strength of our collective membership, AWG looks forward to continued engagement with key stakeholders to remove hurdles...

Read More

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2017

WASHINGTON, Oct. 3, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at IDWeek 2017 taking place in San Diego from October 4 – 8. In addition to 59 poster presentations, representatives from AWG member companies will be participating in various panels and symposiums addressing the current state of the antimicrobial development pipeline. IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases. “AWG is proud to share data from our member companies at IDWeek this year,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “AWG member presentations span topics from preclinical and clinical studies on new antibacterial and antifungal drugs to the diagnostics of and research on emerging resistant bacterial and fungal pathogens. These presentations highlight the latest developments in the fight against superbugs and drug resistant infections.” For more information on AWG member company posters and participation please visit: http://www.antimicrobialsworkinggroup.org/news/idweek-2017/. About The Antimicrobials Working Group AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial...

Read More

Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program

WASHINGTON, Sept. 6, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) is pleased to announce that two of its member companies, T2 Biosystems, Inc. (NASDAQ: TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, and Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, have entered into an exclusive partnership for commercial placement of T2Dx Instruments to support CD101 drug trials. The program is designed to accelerate enrollment in Cidara’s CD101 trials targeting the deadly sepsis-causing pathogen Candida, and to increase uptake of T2’s products. “The AWG is excited to highlight this collaboration between two of its member companies,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “We believe that this and other such partnerships between diagnostic and therapeutic companies will play a vital role in combatting the global health threat of antimicrobial resistance, and ultimately will improve patient care.” About T2 Biosystems T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet...

Read More

T2 Biosystems and Aridis Pharmaceuticals, Inc. Join Antimicrobials Working Group

WASHINGTON, Aug. 15, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of two new members to their group of 12 companies with the mission to combat drug resistant infections and spur life-saving innovations. T2 Biosystems, Inc. (NASDAQ: TTOO), is an emerging leader in the development of innovative diagnostic products to improve patient health, and is AWG’s first diagnostic member company. Aridis Pharmaceuticals, Inc. is a biopharmaceutical company applying proprietary technologies to produce novel immunotherapeutics for infectious diseases. “Diagnostics play a vital role in providing the best possible patient care and combatting the global health threat of antimicrobial resistance,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “T2 Biosystems is a leading innovator in the field and their T2MR detection technology enables the delivery of life-saving medicines more rapidly to patients and reduces the use of unnecessary drug exposure. We’re excited to have their expertise in the fight against superbugs and drug resistant infections. In addition, I believe that immunotherapeutics, such as those being developed by Aridis, represent the wave of the future and will become an increasingly important source of potent, highly selective treatments in our antimicrobial armamentarium.” “T2 is proud...

Read More

Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel

WASHINGTON, June 19, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today that Jeffrey Stein, Ph.D., Chairman of AWG and President and Chief Executive Officer of Cidara Therapeutics, Inc. (Nasdaq: CDTX), Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, Inc. (Nasdaq: SCYX), and Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet Pharmaceuticals, Inc. will be participating in an interactive panel discussion at the 2017 BIO International Convention, taking place June 19-22 in San Diego, CA. The panel titled, “Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals” will focus on the growing global public health epidemic caused by fungal infections and highlight the urgent needs and development opportunities in the space. Details for the panel session are as follows: Session Title: Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals  Session ID: 22252 Date and time: Tuesday, June 20, 2017, at 4:15 p.m. PT Location: San Diego Convention Center, Room 9, Upper Level Panelists: Jeffrey Stein, Ph.D., President and Chief Executive Officer, Cidara Therapeutics Marco Taglietti, M.D., President and Chief Executive Officer, SCYNEXIS Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer, Viamet Pharmaceuticals Tom Chiller, M.D., M.P.H., Chief, Mycotic Diseases Branch, Centers for Disease Control and Prevention (CDC) Tim Cooke, Ph.D., Chief Executive Officer,...

Read More

Antimicrobials Working Group Announces New Leadership Team

WASHINGTON, Jan. 11, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the election of a new Chairman, Jeffrey Stein, Ph.D., President and CEO of Cidara Therapeutics, Inc. (NASDAQ: CDTX), as well as Vice Chairs Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) and Eugene Sun, M.D., CEO of Melinta Therapeutics. Dr. Prabhavathi Fernandes has stepped down from her role as Chair of AWG after three years of service. “On behalf of the AWG I would like to thank Dr. Fernandes for her service to the AWG membership since 2013. Under her leadership the coalition has grown substantially and has become increasingly influential in driving legislation and public policy that is accelerating the development of new drugs to combat drug resistant pathogens. She will be sorely missed; we wish her well in her retirement,” said Jeff Stein, incoming Chairman. About The Antimicrobials Working Group: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging antibiotics and antifungal companies. Today, AWG is comprised of thirteen antimicrobials companies: Amplyx Pharmaceuticals, Arsanis Inc., Cempra Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Nabriva Therapeutics US Inc.,...

Read More